Analysts Set GoodRx Holdings, Inc. (NASDAQ:GDRX) PT at $8.78

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) have been given a consensus rating of "Hold" by the nineteen ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $8.78.

GDRX has been the subject of several recent analyst reports. Leerink Partnrs restated an "outperform" rating on shares of GoodRx in a research report on Monday, February 26th. The Goldman Sachs Group lifted their target price on GoodRx from $6.50 to $7.50 and gave the company a "neutral" rating in a research report on Friday, March 1st. Royal Bank of Canada lifted their target price on GoodRx from $7.00 to $8.00 and gave the company a "sector perform" rating in a research report on Friday, March 1st. KeyCorp upgraded shares of GoodRx from a "sector weight" rating to an "overweight" rating and set a $9.00 price objective for the company in a research report on Wednesday, April 10th. Finally, TD Cowen upped their price objective on shares of GoodRx from $12.00 to $14.00 and gave the stock an "outperform" rating in a research report on Friday, March 1st.

GoodRx Price Performance

Shares of NASDAQ GDRX traded down $0.03 during mid-day trading on Tuesday, reaching $6.52. The company had a trading volume of 1,277,379 shares, compared to its average volume of 1,582,869. The business's 50-day simple moving average is $6.87 and its 200 day simple moving average is $6.18. GoodRx has a one year low of $4.14 and a one year high of $9.37. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.85.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings data on Thursday, February 29th. The company reported $0.02 EPS for the quarter, meeting the consensus estimate of $0.02. GoodRx had a negative net margin of 1.18% and a positive return on equity of 2.45%. The business had revenue of $196.64 million during the quarter, compared to the consensus estimate of $195.59 million. As a group, sell-side analysts forecast that GoodRx will post 0.23 EPS for the current fiscal year.

Institutional Trading of GoodRx

A number of large investors have recently bought and sold shares of GDRX. Moneta Group Investment Advisors LLC grew its position in shares of GoodRx by 112,694.0% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 17,148,069 shares of the company's stock worth $79,910,000 after buying an additional 17,132,866 shares during the period. Vanguard Group Inc. grew its holdings in GoodRx by 2.1% in the third quarter. Vanguard Group Inc. now owns 8,681,111 shares of the company's stock worth $48,875,000 after purchasing an additional 177,961 shares during the period. Rubric Capital Management LP acquired a new stake in GoodRx in the fourth quarter worth $39,348,000. Millennium Management LLC grew its stake in shares of GoodRx by 151.3% in the 4th quarter. Millennium Management LLC now owns 5,318,603 shares of the company's stock valued at $24,785,000 after buying an additional 3,202,061 shares during the period. Finally, Ameriprise Financial Inc. grew its stake in shares of GoodRx by 459.0% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,631,227 shares of the company's stock valued at $14,814,000 after buying an additional 2,160,541 shares during the period. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.